Advertisement

Volume 132, Issue 10

 

 

September 6, 2018 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Bone loss in murine hemophilic joints is mediated by iRhom2/ADAM17/TNF-α pathway. See the article by Haxaire et al.

Glutamine via α-ketoglutarate dehydrogenase provides succinyl-CoA for heme synthesis during erythropoiesis
In a plenary paper, Burch et al describe a paradigm-shifting mechanism for heme biosynthesis that provides insight into erythropoiesis and may have important clinical correlates.


BCL-2 inhibition in AML: an unexpected bonus?
In a Blood Spotlight, Konopleva and Letai discuss the biologic and preclinical data supporting the use of BCL-2 inhibitors in acute myeloid leukemia (AML), and present the early clinical data supporting their efficacy, especially in combination with other active agents.


von Willebrand factor enhanced microvesicle-induced vascular leakage and coagulopathy in mice with traumatic brain injury
Wu et al provide important insight into the pathophysiology of coagulopathy in traumatic brain injury, demonstrating in mice that von Willebrand factor (VWF) mediates microvesicle-induced coagulopathy that can be blocked by ADAMTS13.


Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92
Morelli et al target the supposedly untargetable MYC gene in multiple myeloma by blocking upregulation of antiapoptotic proteins that counter MYC-induced apoptosis. MIR17PTi induces degradation of the MIR17HG primary transcript, downregulating a cluster of mature microRNAs (miRs) targeting proapoptotic proteins.


Nonviral RNA chimeric antigen receptor–modified T cells in patients with Hodgkin lymphoma
Svoboda and colleagues provide proof-of-principle that chimeric antigen receptor T cells can be made using electroporation rather than viral vectors, and demonstrate transient activity in patients with relapsed refractory Hodgkin lymphoma.


Insight into origins, mechanisms, and utility of DNA methylation in B-cell malignancies
In a Perspective, Oakes and Martin-Subero review the role of epigenetics in B-cell malignancies, highlighting how the understanding of the complex DNA methylation patterns that define normal B-cell maturation as well as B-cell tumor subtypes can potentially inform therapy.


Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNF-α pathway
Haxaire and colleagues investigate the pathophysiology of bone loss in murine hemophilic joints, demonstrating that intraarticular blood stimulates the iRhom2/ADAM17/TNF-α pathway, and that tumor necrosis factor (TNF) inhibition prevents bone loss.

View this week's complete table of contents

Why Submit to Blood?

 


Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.